Ionis Pharmaceuticals (IONS) Expected to Release Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($1.22) per share and revenue of $181.56 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 10:30 AM ET.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $43.68 on Wednesday. The firm’s 50-day moving average is $49.95 and its two-hundred day moving average is $67.38. Ionis Pharmaceuticals has a 12 month low of $42.08 and a 12 month high of $86.74. The company has a market capitalization of $7.26 billion, a PE ratio of -12.63 and a beta of 0.38.

Insider Buying and Selling at Ionis Pharmaceuticals

In other news, EVP Shannon L. Devers sold 1,357 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $43.54, for a total value of $59,083.78. Following the completion of the transaction, the executive vice president owned 17,811 shares in the company, valued at approximately $775,490.94. This trade represents a 7.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden acquired 15,000 shares of the stock in a transaction dated Thursday, July 30th. The shares were bought at an average cost of $53.38 per share, with a total value of $800,700.00. Following the completion of the transaction, the director owned 19,000 shares of the company’s stock, valued at approximately $1,014,220. This represents a 375.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 1.81% of the company’s stock.

Analyst Ratings Changes

IONS has been the topic of several analyst reports. Canaccord Genuity Group reduced their price target on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, October 15th. Royal Bank Of Canada decreased their price target on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Citigroup reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, October 21st. Finally, Morgan Stanley cut their price objective on Ionis Pharmaceuticals from $110.00 to $104.00 and set an “overweight” rating for the company in a research report on Tuesday, September 8th. Nineteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.48.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome.